JP2024524922A5 - - Google Patents

Info

Publication number
JP2024524922A5
JP2024524922A5 JP2023577531A JP2023577531A JP2024524922A5 JP 2024524922 A5 JP2024524922 A5 JP 2024524922A5 JP 2023577531 A JP2023577531 A JP 2023577531A JP 2023577531 A JP2023577531 A JP 2023577531A JP 2024524922 A5 JP2024524922 A5 JP 2024524922A5
Authority
JP
Japan
Prior art keywords
domain
seq
protease
amino acid
optionally
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023577531A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024524922A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/033893 external-priority patent/WO2022266396A1/en
Publication of JP2024524922A publication Critical patent/JP2024524922A/ja
Publication of JP2024524922A5 publication Critical patent/JP2024524922A5/ja
Pending legal-status Critical Current

Links

JP2023577531A 2021-06-16 2022-06-16 武装化キメラ受容体及びその使用方法 Pending JP2024524922A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163211468P 2021-06-16 2021-06-16
US63/211,468 2021-06-16
US202263305155P 2022-01-31 2022-01-31
US63/305,155 2022-01-31
PCT/US2022/033893 WO2022266396A1 (en) 2021-06-16 2022-06-16 Armed chimeric receptors and methods of use thereof

Publications (2)

Publication Number Publication Date
JP2024524922A JP2024524922A (ja) 2024-07-09
JP2024524922A5 true JP2024524922A5 (enExample) 2024-08-06

Family

ID=84526773

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023577531A Pending JP2024524922A (ja) 2021-06-16 2022-06-16 武装化キメラ受容体及びその使用方法

Country Status (9)

Country Link
US (1) US20240277766A1 (enExample)
EP (1) EP4355341A4 (enExample)
JP (1) JP2024524922A (enExample)
KR (1) KR20240022575A (enExample)
AU (1) AU2022294896A1 (enExample)
CA (1) CA3221897A1 (enExample)
IL (1) IL309161A (enExample)
TW (1) TW202317753A (enExample)
WO (1) WO2022266396A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3873540A4 (en) 2018-10-31 2022-07-27 Mayo Foundation for Medical Education and Research METHODS AND MATERIALS FOR THE TREATMENT OF CANCER
CA3116412A1 (en) 2018-10-31 2020-05-07 Humanigen, Inc. Materials and methods for treating cancer
WO2020092839A1 (en) 2018-10-31 2020-05-07 Mayo Foundation For Medical Education And Research Methods and materials for treating cancer
WO2024102943A1 (en) * 2022-11-09 2024-05-16 Senti Biosciences, Inc. Armed chimeric receptors and methods of use thereof
WO2024107670A1 (en) * 2022-11-16 2024-05-23 Regeneron Pharmaceuticals, Inc. Chimeric proteins comprising membrane bound il-12 with protease cleavable linkers
WO2025106924A1 (en) * 2023-11-16 2025-05-22 Senti Biosciences, Inc. Methods of enhancing engineered immune cell cytotoxicity
WO2025179221A1 (en) * 2024-02-22 2025-08-28 Senti Biosciences, Inc. Compositions and methods for armored cell based therapies
WO2026077446A1 (en) * 2024-10-12 2026-04-16 Nanjing Legend Biotech Co., Ltd. Engineered il-15 constructs and uses thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130195800A1 (en) * 2010-03-23 2013-08-01 Intrexon Corporation Vectors Conditionally Expressing Therapeutic Proteins, Host Cells Comprising the Vectors, and Uses Thereof
CA3049652A1 (en) * 2017-01-10 2018-07-19 Intrexon Corporation Modulating expression of polypeptides via new gene switch expression systems
BR112020000731A2 (pt) * 2017-07-12 2020-07-14 Refuge Biotechnologies, Inc. métodos e sistemas para a regular condicionalmente a expressão genética
US20210094994A1 (en) * 2018-04-27 2021-04-01 Baylor College Of Medicine Car t cells with one or more interleukins
TWI809130B (zh) * 2018-06-22 2023-07-21 美商凱特製藥公司 嵌合跨膜蛋白及其用途
TW202035685A (zh) * 2018-10-17 2020-10-01 美商聖堤生物科技股份有限公司 組合癌症免疫療法
WO2020118634A1 (zh) * 2018-12-13 2020-06-18 科济生物医药（上海）有限公司 靶向gpc3的免疫效应细胞及其应用
CN114375198A (zh) * 2019-05-16 2022-04-19 波士顿大学董事会 受调控的合成基因表达系统
US20220396609A1 (en) * 2019-11-01 2022-12-15 Senti Biosciences, Inc. Chimeric receptor sensors
CN115087466A (zh) * 2019-12-12 2022-09-20 森迪生物科学公司 用于细胞的调控装甲的方法和组合物
CA3197147A1 (en) * 2020-11-04 2022-05-12 Senti Biosciences, Inc. Protein payload release

Similar Documents

Publication Publication Date Title
JP6995151B2 (ja) ｓｙｎＴａｃポリペプチド及びその使用
TWI800506B (zh) 免疫結合物
KR102619015B1 (ko) 면역 반응을 조절하는 방법
KR102907737B1 (ko) 재조합 pMHC II형 분자
EP3472205B1 (en) Chimeric antigen receptor
JP2022084852A (ja) キメラポリペプチド及びその使用
CN110352245A (zh) 可分泌变体免疫调节蛋白和工程化细胞疗法
JP2019525771A5 (enExample)
WO2020163646A1 (en) Anti-gitr antigen-binding domains and uses thereof
CN118852460A (zh) 具有非FcγR依赖性激动活性的肿瘤坏死因子(TNF)受体超家族(TNFRSF)受体-激活抗体融合蛋白(具有非FcγR依赖性激动活性的TNFRSF受体-激活抗体融合蛋白；TRAAFFIAA)
JP2020512814A (ja) 免疫抱合体
EP3735417A1 (en) Multi-domain immunomodulatory proteins and methods of use thereof
JP2018529363A5 (enExample)
KR20180057720A (ko) 다가 Fv 항체
CN110088126A (zh) Icos配体变体免疫调节蛋白及其用途
JP2023138962A (ja) Ｃｔｌａ－４変異型免疫調節タンパク質およびそれらの使用
CN115836087A (zh) 抗cd26蛋白及其用途
WO2019118518A2 (en) Inducible cell receptors for cell-based therapeutics
US20240376177A1 (en) Multimeric t-cell modulatory polypeptides and methods of use thereof
CN120051292A (zh) Il-18融合蛋白以及生产il-18的方法
CN121532203A (zh) Il-18融合蛋白的使用方法
TW202144396A (zh) 抑制性嵌合受體架構
Ashkenazi et al. Immunoadhesins: an alternative to human monoclonal antibodies
WO2024118539A2 (en) Engineered interleukin-10 and fusion proteins thereof
JP2023518835A (ja) 制御性ｔ細胞の除去用の二重特異性融合タンパク質